Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2023-02-13 5:47 pm Purchase |
2022-12-31 | 13G | Verona Pharma plc VRNA |
VIVO VENTURES VII LLC | 23,142,200 3.800% |
23,142,200 (New Position) |
Filing History |
| 2023-02-09 3:57 pm Sale |
2023-02-08 | 13G | Verona Pharma plc VRNA |
Access Industries Holdings LLC | 32,946,296 5.450% |
-18,165,352 (-35.54%) |
Filing History |
| 2023-02-06 2:36 pm Purchase |
2022-12-30 | 13G | Verona Pharma plc VRNA |
WELLINGTON MANAGEMENT CO LLP | 26,770,960 4.430% |
26,770,960 (New Position) |
Filing History |
| 2022-12-27 4:25 pm Sale |
2022-12-22 | 13D | 89bio, Inc. ETNB |
ORBIMED ADVISORS LLC | 4,260,691 5.600% |
-767,483 (-15.26%) |
Filing History |
| 2022-09-07 5:28 pm Purchase |
2022-08-15 | 13D | Verona Pharma plc VRNA |
Growth Equity Opportunities Fund IV, LLC | 46,447,651 7.900% |
3,809,520 (+8.93%) |
Filing History |
| 2022-08-12 2:29 pm Purchase |
2022-08-10 | 13D | 89bio, Inc. ETNB |
ORBIMED ADVISORS LLC | 5,028,174 6.900% |
5,028,174 (New Position) |
Filing History |
| 2022-08-11 4:54 pm Purchase |
2022-04-29 | 13D | Verona Pharma plc VRNA |
Abingworth LLP | 21,313,822 4.400% |
249,600 (+1.18%) |
Filing History |
| 2022-08-10 4:57 pm Purchase |
2022-08-09 | 13G | Verona Pharma plc VRNA |
Access Industries Holdings LLC | 51,111,648 10.480% |
6,667,200 (+15.00%) |
Filing History |
| 2022-02-14 4:11 pm Purchase |
2021-12-31 | 13G | Verona Pharma plc VRNA |
RA Capital Management, L.P. | 48,778,172 9.990% |
7,235,168 (+17.42%) |
Filing History |
| 2022-02-11 5:20 pm Unchanged |
2021-12-31 | 13G | Verona Pharma plc VRNA |
Vivo Ventures VI LLC | 23,493,716 4.900% |
0 (Unchanged) |
Filing History |
| 2022-02-04 09:06 am Purchase |
2021-12-31 | 13G | Verona Pharma plc VRNA |
WELLINGTON MANAGEMENT CO LLP | 38,655,904 8.340% |
38,655,904 (New Position) |
Filing History |
| 2021-02-16 4:34 pm Purchase |
2020-12-31 | 13G | Verona Pharma plc VRNA |
RA Capital Management, L.P. | 41,543,004 9.990% |
41,543,004 (New Position) |
Filing History |
| 2021-02-05 4:38 pm Sale |
2021-02-02 | 13G | Verona Pharma plc VRNA |
Novo Holdings A/S | 12,893,250 3.100% |
-9,746,417 (-43.05%) |
Filing History |
| 2020-10-05 4:47 pm Sale |
2020-09-30 | 13D | Verona Pharma plc VRNA |
Novo Holdings A/S | 22,639,667 5.400% |
-408,832 (-1.77%) |
Filing History |
| 2020-08-03 4:18 pm Purchase |
2020-07-22 | 13D | Verona Pharma plc VRNA |
Growth Equity Opportunities Fund IV, LLC | 42,638,131 10.200% |
31,111,112 (+269.90%) |
Filing History |
| 2020-07-31 4:05 pm Purchase |
2020-07-22 | 13D | Verona Pharma plc VRNA |
Abingworth LLP | 21,064,222 5.100% |
12,444,448 (+144.37%) |
Filing History |
| 2020-07-24 5:20 pm Purchase |
2020-07-22 | 13G | Verona Pharma plc VRNA |
Access Industries Holdings LLC | 44,444,448 10.700% |
44,444,448 (New Position) |
Filing History |
| 2020-07-24 4:30 pm Purchase |
2020-07-22 | 13D | Verona Pharma plc VRNA |
Novo Holdings A/S | 23,048,499 5.500% |
8,888,888 (+62.78%) |
Filing History |
| 2020-07-24 4:30 pm Purchase |
2020-07-22 | 13G | Verona Pharma plc VRNA |
Vivo Ventures VI LLC | 23,493,716 5.700% |
12,444,448 (+112.63%) |
Filing History |